Sign up to receive product release notifications:
We are building a universal platform to revolutionize how diseases are diagnosed, categorized, and treated.
Through integrating massive amounts of high-resolution molecular sequencing data, we find novel disease patterns that legacy methods miss.
This allows us to develop better tests and treatment strategies for a wide range of conditions, including cancers and autoimmune diseases.
Our platform continuously learn from biological data collected in real-time to improve predictive capabilities over time, helping translate data to patient impact faster.
Data Collection At Scale
We use an AI-driven, agentic data pipeline to autonomously discover, acquire, and integrate thousands of biological samples in real time, creating a continuously updated snapshot of molecular data.
AI-Powered Insights
Using our database we train foundational deep learning models to identify generalizable biological patterns to predict how a patients disease may progress or respond to treatments.
Faster, More Accurate Prognostics
We refine and optimize biological patterns into molecular signatures using our deep learning models to maximize their robustness and predictive performance, enabling a scalable process for prognostic tests discovery.
By The Numbers
To date, our fully automated database contains information from 30,000+ samples indexed from 6,000+ studies, encompassing over 240 million cellular profiles from hundreds of diseases and multiple species.
We actively work with biotechs, research institutions, and life sciences organizations to bring our technology into real-world applications.
Biopharma
Improve drug development using our realtime database for early target discovery.
Life Sciences
Build more accurate, AI-powered prognostic and diagnostic for disease detection and monitoring.
Research
Access harmonized, high-resolution data to drive new innovations and discoveries.
Experience at the nexus of genomic technology, data science, artificial intelligence, and life science commercialization
Robert Sebra, PhD
Co-Founder, CEO
Professor, Genetics & Genomic Sciences Director, Center for Advanced Genomic Technologies, Icahn School of Medicine at Mount Sinai
Founding director of the Center for Advanced Genomics Technology at ISMMS. Renowned expert in Genomic Technology development and Functional Genomics with patented surface chemistry and sequencing platforms, 230 manuscripts with >23,000 citations spanning molecular and computational science.
Executive leadership experience in biotechnology across both public and private sectors having experienced IPO with Pacific Biosciences (2007-2012) and Sema4/GeneDx (2016-2022).
Daniel Charytonowicz, PhD
Co-Founder, CSO
MSTP Program, Icahn School of Medicine at Mount Sinai
Spearheaded design and development of Panacent Bio’s original end-to-end machine learning platform.
Experienced practitioner with knowledge in Functional Genomics, Machine Learning, Software Engineering, Bioinformatics, and Medicine.
Prior strategic consulting & startup founder experience in genomics and healthcare sectors.
Chris Gutnajer
Head of Software Engineering
Former Software Engineer,
Google & Johns Hopkins APL
Previous experience at Google and the Johns Hopkins University Applied Physics Lab. Engineered cutting edge machine learning applications, distributed software systems, and large scale data infrastructure systems.
Key experience with delivering observable, revenue critical, regulatory compliant systems imperative to translate future, AI-augmented platforms broadly.
Tim O'Connor, PhD
Machine Learning Engineer
Former Machine Learning Engineer, CytoVeris
Extensive engineering experience in developing end-to-end computer vision and machine learning platforms for disease screening and cancer detection.
Proven track record in research and startup environments, collaborating with clinicians to deliver innovative machine learning solutions that address critical medical needs.
Motivated to use machine learning to leverage biological data, transform healthcare practices, and improve patient care.
Steve Beauchaw
CFO
Former Partner, DeciBo
Former Executive Director, Morgan Stanley Life Sciences
Built life science tools and diagnostics investment research teams at Morgan Stanley and Wolfe Research, and was nationally ranked at both firms.
Has taken five companies public, including PHC Holdings in Tokyo while also part of the strategic turnaround team.
Opened the New York-based investor service effort for DeciBio, where Steve remains an advisor.
Daniel Clark, JD
General Counsel
Former General Counsel, Sema4
Experience in life sciences, healthcare, and genomic data, combined with a broad-based legal background.
Proven track record of raising over one billion dollars in growth capital through public and private vehicles, taking a company public, and closing M&A and other large transactions.
Excelled in building and running lean, practical, and effective legal, compliance, and risk management functions to support growth and efficient business operations.
Get in touch with us to learn more.
